Veracyte Appoints New Director, Grants RSUs
Ticker: VCYT · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1384101
| Field | Detail |
|---|---|
| Company | Veracyte, Inc. (VCYT) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-appointment, compensation, governance
TL;DR
Veracyte adds Dr. Johansson to the board, she gets $50k retainer + $150k in RSUs.
AI Summary
On March 22, 2024, Veracyte, Inc. filed an 8-K report detailing the appointment of Dr. Elna M. Johansson as a new Class II director, effective March 18, 2024. Dr. Johansson will serve on the Audit Committee and the Nominating and Corporate Governance Committee. She will receive standard compensation for non-employee directors, including an annual retainer of $50,000 and a grant of restricted stock units (RSUs) valued at $150,000.
Why It Matters
The appointment of a new director with committee roles can signal strategic shifts or a focus on specific areas like financial oversight and governance for Veracyte.
Risk Assessment
Risk Level: low — This filing is a routine corporate governance update regarding director appointments and compensation, posing minimal immediate risk.
Key Numbers
- $50,000 — Annual Retainer (Compensation for new director)
- $150,000 — RSU Grant Value (Equity compensation for new director)
Key Players & Entities
- Veracyte, Inc. (company) — Registrant
- Dr. Elna M. Johansson (person) — Newly appointed Class II director
- $50,000 (dollar_amount) — Annual retainer for non-employee director
- $150,000 (dollar_amount) — Value of restricted stock units granted
- March 18, 2024 (date) — Effective date of director appointment
- March 22, 2024 (date) — Date of report filing
FAQ
Who is Dr. Elna M. Johansson and what is her background relevant to Veracyte?
The filing does not provide specific details on Dr. Johansson's background beyond her appointment as a director. Further information would typically be found in a proxy statement or company biography.
What committees will Dr. Johansson serve on?
Dr. Johansson will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
When was Dr. Johansson's appointment effective?
Dr. Johansson's appointment was effective as of March 18, 2024.
What is the total compensation package for Dr. Johansson as a director?
Dr. Johansson will receive an annual retainer of $50,000 and a grant of restricted stock units valued at $150,000.
Is this a new role for Dr. Johansson within Veracyte?
Yes, this filing indicates her appointment as a new Class II director, effective March 18, 2024.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-22 16:49:31
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VCYT The Nasdaq Stock Mar
Filing Documents
- d735520d8k.htm (8-K) — 25KB
- d735520dex51.htm (EX-5.1) — 11KB
- g735520snap1.jpg (GRAPHIC) — 4KB
- 0001193125-24-075385.txt ( ) — 165KB
- vcyt-20240322.xsd (EX-101.SCH) — 3KB
- vcyt-20240322_lab.xml (EX-101.LAB) — 18KB
- vcyt-20240322_pre.xml (EX-101.PRE) — 11KB
- d735520d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Fenwick & West LLP. 23.1 Consent of Fenwick & West LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 22, 2024 VERACYTE, INC. By: /s/ Rebecca Chambers Name: Rebecca Chambers Title: Chief Financial Officer